Last updated: August 25, 2026
ecutive summary: Aliskiren is a mature, genericized direct renin inhibitor with limited branded demand and substantial safety restrictions. The strongest commercial opportunities are not conventional hypertension tablets. They are differentiated formulations that improve adherence, swallowing, pediatric administration, food-effect management, or fixed-dose combination positioning. Excipient selection should prioritize dissolution robustness, moisture control, dose uniformity, and compatibility with aliskiren hemifumarate. The main commercial constraint is clinical: aliskiren is contraindicated with ACE inhibitors or angiotensin receptor blockers in patients with diabetes and is generally avoided in patients with renal impairment because of hyperkalemia, hypotension, and renal adverse events.
Aliskiren Excipient Strategy and Commercial Opportunities
What is aliskiren and how is it supplied?
Aliskiren is an orally active, nonpeptide direct renin inhibitor. Novartis marketed it in the United States as Tekturna and in Europe as Rasilez. The active pharmaceutical ingredient is generally supplied as aliskiren hemifumarate.
The approved product is an immediate-release, film-coated tablet administered once daily. U.S. strengths are 150 mg and 300 mg aliskiren, with dosing adjusted according to blood-pressure response and tolerability.[1]
| Attribute |
Aliskiren |
| Pharmacologic class |
Direct renin inhibitor |
| Active ingredient |
Aliskiren hemifumarate |
| Reference U.S. product |
Tekturna |
| Reference European product |
Rasilez |
| Route |
Oral |
| Approved form |
Immediate-release film-coated tablet |
| Typical strengths |
150 mg and 300 mg |
| Primary indication |
Hypertension |
| Original U.S. approval |
2007 |
| Originator |
Novartis |
| Generic status |
Generic oral tablets are available in the U.S. |
| Biosimilar relevance |
None; aliskiren is a small molecule |
| Key safety constraints |
Hyperkalemia, hypotension, renal impairment, drug interactions |
Aliskiren has low systemic bioavailability, reported at approximately 2.5%, and is affected by intestinal and hepatic transport mechanisms, including P-glycoprotein.[1,2] These characteristics create formulation opportunities, but they also make bioequivalence and food-effect control central to development.
What excipients are used in Tekturna and generic aliskiren tablets?
The reference tablet uses conventional direct-compression or dry-granulation excipient technology. The U.S. prescribing information identifies excipient classes that include microcrystalline cellulose, crospovidone, povidone, colloidal silicon dioxide, magnesium stearate, hypromellose, talc, titanium dioxide, and iron oxides, depending on tablet strength and coating composition.[1]
Functional role of the main excipients
| Excipient class |
Function in aliskiren tablets |
Development considerations |
| Microcrystalline cellulose |
Diluent and compression aid |
Supports tablet hardness and size control |
| Crospovidone |
Superdisintegrant |
Important for rapid tablet breakup and dissolution |
| Povidone |
Binder |
Supports granule strength and content uniformity |
| Colloidal silicon dioxide |
Glidant and moisture-control aid |
Improves powder flow; excessive levels can slow dissolution |
| Magnesium stearate |
Lubricant |
Over-lubrication can reduce tablet wettability |
| Hypromellose |
Film former |
Supports coating integrity and appearance |
| Talc |
Anti-tacking and coating aid |
Requires control of particle size and coating dispersion |
| Titanium dioxide and iron oxides |
Opacifiers and colorants |
Affect appearance, light protection, and market-specific compliance |
The reference composition does not create a high technical barrier by itself. A generic manufacturer can usually reproduce the immediate-release profile with standard excipients, provided it controls particle-size distribution, blend uniformity, compression force, lubrication time, and dissolution.
How should an excipient strategy address aliskiren’s formulation risks?
The formulation strategy should focus on four risks: low and variable bioavailability, food-related exposure changes, dose uniformity, and tablet acceptability.
Solubility and dissolution
Aliskiren hemifumarate is water soluble relative to many poorly soluble drug substances, but solubility alone does not determine systemic exposure. Low bioavailability is linked to extensive presystemic disposition and transporter effects. Increasing dissolution beyond the reference product may not proportionally increase exposure and could complicate bioequivalence.
The preferred approach for a conventional generic is therefore controlled, reproducible immediate release rather than aggressive solubility enhancement. Suitable development options include:
- Crospovidone or croscarmellose sodium for rapid disintegration.
- Microcrystalline cellulose or mannitol for compactability.
- Povidone or low-substituted hydroxypropyl cellulose for binding.
- Colloidal silicon dioxide for flow improvement.
- Low-level surfactants only where comparative dissolution and pharmacokinetic data support their use.
Surfactant-based formulations, amorphous solid dispersions, lipid systems, and nanosuspensions may increase exposure but can also alter food sensitivity and transporter-mediated absorption. Those technologies are better suited to differentiated products than to a low-cost generic tablet.
Moisture and chemical stability
Aliskiren hemifumarate formulations should be evaluated for moisture sensitivity, solid-state conversion, and degradation under high humidity. An excipient system with low residual moisture and low hygroscopicity can simplify stability control.
Packaging is part of the excipient strategy. High-barrier blister packaging or a bottle with a desiccant may protect product quality more effectively than adding excipients to the tablet. For a low-volume product, blister packaging can be commercially rational if it reduces stability failures and supports unit-dose adherence.
Lubrication and dissolution
Magnesium stearate is effective but hydrophobic. Excessive concentration or prolonged blending may reduce wetting and slow dissolution. A manufacturer seeking a robust generic profile should optimize:
- Lubricant concentration.
- Lubrication time.
- Compression force.
- Tablet porosity.
- Disintegration time.
This is a practical area for process differentiation. A formulation with the same broad excipient classes as Tekturna can still fail comparative dissolution if lubrication and compression are poorly controlled.
Colorants and coating materials
Film coating has limited pharmacologic value but affects patient acceptance, identification, light protection, and supply-chain control. Iron oxides, titanium dioxide, hypromellose, and talc are well-established options. Global products may require alternate color systems because of regional restrictions, customer preferences, or concerns about titanium dioxide.
A color-free or reduced-color formulation could support institutional purchasing, pediatric use, or markets where excipient labeling is tightly scrutinized. The opportunity is commercial rather than patent-driven.
What formulations are protected or commercially differentiated for aliskiren?
The reference product is an immediate-release tablet. The principal formulation opportunities are oral liquids, orally disintegrating tablets, multiparticulates, and fixed-dose combinations.
Pediatric oral liquid
A liquid formulation is the clearest unmet dosage-form opportunity, although the approved hypertension labeling is primarily tablet-based. A liquid could improve administration for children, older adults, patients with dysphagia, and patients receiving enteral nutrition.
Key excipient issues include:
- Suspension stability or true solution stability.
- Palatability and bitterness control.
- Preservative compatibility.
- Syringe dosing accuracy.
- Container adsorption.
- Compatibility with feeding tubes.
- Control of pH and precipitation after dilution.
Aliskiren’s pharmacokinetic and safety profile limits the size of the pediatric opportunity. A liquid would require a defined clinical and regulatory use case, not merely a reformulation of the adult tablet.
Orally disintegrating tablet
An orally disintegrating tablet could target dysphagia and adherence. Crospovidone, mannitol, microcrystalline cellulose, and low-moisture compression systems are reasonable starting points. Taste masking is the central challenge because rapid disintegration increases exposure of the drug substance to taste receptors.
Potential taste-masking systems include:
- Ion-exchange resins.
- Polymer coating of drug particles.
- Lipid barriers.
- Sweetener and flavor systems.
- Compressed multilayer structures.
Taste masking must not delay release after swallowing or materially change exposure. The product would need comparative dissolution and pharmacokinetic evaluation against the reference tablet.
Modified-release formulation
Modified release has weaker commercial logic. Aliskiren is already administered once daily, so extended release offers limited adherence benefit. It could theoretically reduce peak-related adverse effects or smooth exposure, but any advantage would require clinical evidence. The development cost and regulatory burden would be difficult to justify in a mature, low-growth hypertension market.
Fixed-dose combinations
Fixed-dose combinations are commercially more credible because hypertension treatment often uses multiple agents. Potential combinations include aliskiren with:
- A thiazide or thiazide-like diuretic.
- A calcium-channel blocker.
- A statin or cardiometabolic therapy, although such combinations require a strong prescribing rationale.
Aliskiren combinations with ACE inhibitors or ARBs face major clinical restrictions. The FDA warns against combined use in patients with diabetes and advises avoidance in patients with moderate-to-severe renal impairment because of renal, hypotension, and hyperkalemia risks.[3] Those restrictions materially weaken the commercial case for renin-angiotensin combination products.
When did aliskiren lose exclusivity and what is the current generic position?
Aliskiren’s core small-molecule exclusivity has expired, and generic aliskiren tablets are commercially available in the United States. The reference product no longer has the market protection associated with a first-in-class launch.
| Exclusivity issue |
Commercial status |
| Core compound protection |
Expired |
| U.S. small-molecule generic pathway |
ANDA pathway |
| Biosimilar pathway |
Not applicable |
| Paragraph IV risk |
Primarily relevant to any still-listed secondary patent |
| Reference product exclusivity |
No current practical barrier to generic tablet entry |
| Current market barrier |
Clinical demand, safety restrictions, and low commercial volume |
A generic manufacturer should distinguish between formal patent expiry and practical market opportunity. Even after core patent expiry, secondary patents can cover formulations, dosing methods, combinations, or manufacturing processes. For aliskiren, however, the strongest market barrier is the shrinking and restricted clinical niche rather than the complexity of the reference tablet.
What is the Orange Book status of aliskiren?
The FDA Orange Book is the controlling source for current U.S. patent listings, expiration dates, and exclusivity status for Tekturna and related products.[4] Aliskiren is a small-molecule drug, so Orange Book listings, not the Purple Book, govern U.S. reference-product patent analysis.
A current diligence review should examine:
- Tekturna product numbers and strengths.
- Any remaining listed patents.
- Patent-use codes associated with hypertension treatment.
- Whether listed patents are expired, delisted, or subject to statutory certification.
- Approved labeling differences relevant to ANDA carve-outs.
Paragraph IV exposure is now more relevant to secondary patents than to the original aliskiren compound. An ANDA sponsor would need to assess whether a listed patent covers the proposed tablet composition, dosage regimen, combination, or manufacturing process. If no unexpired listed patent blocks the product, the sponsor can pursue ordinary certification and launch timing under the applicable FDA pathway.
Which companies are challenging or competing with aliskiren?
Competition comes from two groups: generic aliskiren suppliers and alternative antihypertensive manufacturers.
Generic competition
Generic aliskiren tablets compete primarily on:
- Approved strengths.
- Wholesale acquisition cost.
- Supply reliability.
- Pharmacy benefit manager contracting.
- Formulation equivalence.
- Packaging and unit-dose capability.
The product is unlikely to support premium pricing without a meaningful dosage-form or adherence advantage.
Therapeutic competition
Aliskiren competes against lower-cost and more established classes:
- ACE inhibitors.
- ARBs.
- Calcium-channel blockers.
- Thiazide diuretics.
- Beta blockers in selected populations.
ARBs and ACE inhibitors have deeper guideline integration and broader commercial use. Aliskiren’s direct renin mechanism has not translated into comparable market penetration, particularly after safety concerns surrounding dual renin-angiotensin system blockade.
How strong is the aliskiren patent estate?
The core patent estate is weak as a present-day barrier because aliskiren is an older small molecule with generic availability. Secondary intellectual property may still have value if it covers a genuinely differentiated formulation or manufacturing process.
| Patent category |
Likely present value |
| Core chemical compound |
Low; expired |
| Salt form |
Low to moderate, depending on jurisdiction and claim status |
| Immediate-release tablet composition |
Low unless narrowly differentiated |
| Pediatric liquid |
Potentially moderate if supported by novel formulation claims |
| Orally disintegrating tablet |
Potentially moderate |
| Fixed-dose combination |
Variable; weakened by clinical restrictions |
| Manufacturing process |
Moderate if it reduces impurities or improves scale-up |
| Solid-state or particle engineering |
Moderate if linked to measurable performance |
| Method of use |
Limited where clinical labeling is narrow or overlapping |
| Packaging |
Usually low patent value; stronger trade-secret value |
The strongest defensible position would combine formulation claims with process know-how, stability data, device or packaging differentiation, and regulatory exclusivity. A simple excipient substitution is unlikely to create durable protection.
What manufacturing and IP barriers affect aliskiren products?
Manufacturing barriers are manageable but not trivial. The active ingredient must be controlled for assay, impurity profile, particle size, polymorphic or salt-state consistency, and blend uniformity. Low-dose and high-dose tablet strengths may require different manufacturing controls because the 150 mg and 300 mg presentations have different tablet masses and coating requirements.
Relevant trade-secret opportunities include:
- Particle-size control.
- Wetting and granulation parameters.
- Lubrication optimization.
- Low-moisture processing.
- Coating uniformity.
- Stability-indicating analytical methods.
- Scale-up controls that preserve dissolution.
A manufacturer can obtain a practical advantage without obtaining a broad composition patent. Reliable supply, low rejection rates, and consistent dissolution may matter more than a narrow secondary patent in a mature generic market.
What licensing deals and commercial partnerships are relevant?
Novartis historically controlled the principal aliskiren assets and commercialized Tekturna and Rasilez. The mature product has limited evidence of a current high-value licensing market. The most plausible transactions involve:
- Regional commercialization rights.
- Generic supply agreements.
- Contract manufacturing.
- Co-development of liquid or orally disintegrating presentations.
- Portfolio acquisitions involving mature cardiovascular products.
A licensing transaction would need a clear economic thesis. The best candidates are geographic markets with limited generic penetration, hospital or institutional channels, or a differentiated dosage form with documented adherence or administration benefits.
What generic launch scenarios exist for aliskiren?
Standard generic tablet launch
This is the lowest-risk route. It uses a conventional immediate-release formulation and competes on price and supply. Commercial returns depend on manufacturing cost and market share rather than product differentiation.
Low-cost regional launch
A supplier can target countries where aliskiren remains prescribed but generic competition is limited. The product must meet local registration, serialization, packaging, and pharmacovigilance requirements. The opportunity is geographic, not based on U.S. exclusivity.
Differentiated adherence product
An orally disintegrating or easy-swallow tablet could command a modest premium if supported by patient and payer evidence. Without reimbursement recognition, the premium is likely to be limited.
Pediatric or dysphagia-focused liquid
This is the highest differentiation opportunity but also the highest clinical and regulatory risk. It requires evidence that the formulation solves a real administration problem without worsening safety or exposure variability.
Combination product
This approach has commercial logic only where the combination avoids the highest-risk dual renin-angiotensin pairings and offers a clinically accepted treatment pathway.
How does aliskiren compare with competing antihypertensive drugs?
| Factor |
Aliskiren |
ACE inhibitors and ARBs |
Calcium-channel blockers |
| Mechanism |
Direct renin inhibition |
Renin-angiotensin system blockade |
Vascular smooth-muscle effects |
| Generic availability |
Yes |
Extensive |
Extensive |
| Guideline penetration |
Lower |
High |
High |
| Once-daily dosing |
Yes |
Often yes |
Often yes |
| Formulation differentiation |
Possible but limited |
Broad generic competition |
Broad generic competition |
| Major safety concern |
Hyperkalemia, renal effects, hypotension |
Cough for ACE inhibitors; renal and potassium effects |
Edema and cardiovascular effects, depending on agent |
| Commercial opportunity |
Niche formulation or regional supply |
Scale and portfolio economics |
Scale, combinations, and institutional channels |
Key Takeaways
- Aliskiren is a mature, genericized small-molecule antihypertensive with no biosimilar pathway.
- The reference dosage form is an immediate-release film-coated tablet using conventional excipients.
- The most relevant excipient variables are disintegration, lubrication, moisture control, tablet hardness, and dissolution.
- A standard generic tablet is commercially feasible but likely to face price pressure.
- Pediatric liquids and orally disintegrating tablets offer the clearest formulation differentiation.
- Modified release has limited commercial justification because the reference product is already once daily.
- Fixed-dose combinations are constrained by the clinical restrictions on dual renin-angiotensin system blockade.
- Core compound exclusivity is expired; current diligence should focus on any surviving secondary Orange Book listings.
- Manufacturing know-how, stability control, reliable supply, and regional access may create more value than broad patent protection.
- The principal market risk is limited demand and safety-driven prescribing restriction, not formulation complexity.
FAQs
Can aliskiren be formulated as an oral suspension?
Yes. A suspension would require control of sedimentation, redispersibility, particle size, preservative compatibility, palatability, and dose uniformity. Its commercial value would depend on pediatric, dysphagia, or enteral-tube use.
Which excipient is most important for aliskiren dissolution?
No single excipient controls performance. Crospovidone, tablet porosity, magnesium stearate level, lubrication time, and compression force collectively determine disintegration and dissolution.
Does aliskiren have biosimilar competition?
No. Aliskiren is a chemically synthesized small molecule. U.S. competitors use the ANDA generic-drug pathway rather than the biosimilar pathway.
Is an aliskiren fixed-dose combination commercially attractive?
Only selectively. Combinations that avoid contraindicated or clinically restricted dual renin-angiotensin blockade are more viable, but competition from established antihypertensive combinations remains intense.
Can an excipient change create new patent protection for aliskiren?
Potentially, but a routine substitution is unlikely to support strong protection. A viable formulation patent generally requires a novel composition or process linked to measurable benefits such as improved stability, palatability, dissolution control, or administration.
References
-
Novartis Pharmaceuticals Corporation. (2023). Tekturna (aliskiren) tablets: U.S. prescribing information. U.S. Food and Drug Administration.
-
Vaidyanathan, S., Jermany, J., Yeh, C., Bizot, M. N., & Dieterich, H. A. (2008). Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clinical Pharmacokinetics, 47(8), 515-526.
-
U.S. Food and Drug Administration. (2012). FDA drug safety communication: New warning and contraindication for blood pressure medicines containing aliskiren. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
